Erin Ann Bohula May, D.Phil., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simvastatin | 10 | 2019 | 352 | 3.110 |
Why?
|
| Anticholesteremic Agents | 12 | 2020 | 987 | 2.450 |
Why?
|
| Coronary Care Units | 5 | 2020 | 235 | 2.080 |
Why?
|
| Acute Coronary Syndrome | 14 | 2019 | 2363 | 2.040 |
Why?
|
| Benzazepines | 5 | 2019 | 311 | 1.880 |
Why?
|
| Shock, Cardiogenic | 5 | 2020 | 731 | 1.430 |
Why?
|
| Cholesterol, LDL | 9 | 2020 | 2417 | 1.100 |
Why?
|
| Myocardial Infarction | 12 | 2020 | 11888 | 1.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2018 | 3329 | 1.020 |
Why?
|
| Anti-Obesity Agents | 2 | 2018 | 229 | 0.960 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2020 | 226 | 0.930 |
Why?
|
| Overweight | 4 | 2019 | 2420 | 0.920 |
Why?
|
| Hypolipidemic Agents | 2 | 2019 | 626 | 0.920 |
Why?
|
| Lactones | 3 | 2016 | 319 | 0.910 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 2 | 2019 | 31 | 0.780 |
Why?
|
| Secondary Prevention | 6 | 2017 | 1550 | 0.770 |
Why?
|
| Appetite Depressants | 2 | 2019 | 108 | 0.760 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 1291 | 0.720 |
Why?
|
| C-Reactive Protein | 3 | 2018 | 3823 | 0.720 |
Why?
|
| Pyridines | 4 | 2016 | 2875 | 0.700 |
Why?
|
| Double-Blind Method | 18 | 2020 | 12386 | 0.690 |
Why?
|
| Obesity | 5 | 2019 | 12896 | 0.560 |
Why?
|
| Cardiovascular Diseases | 10 | 2020 | 15728 | 0.550 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 179 | 0.550 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2020 | 1453 | 0.490 |
Why?
|
| Atherosclerosis | 4 | 2020 | 3525 | 0.480 |
Why?
|
| Receptor, IGF Type 1 | 4 | 2006 | 380 | 0.460 |
Why?
|
| Stroke | 6 | 2020 | 9935 | 0.460 |
Why?
|
| Clinical Chemistry Tests | 1 | 2013 | 58 | 0.440 |
Why?
|
| Dyslipidemias | 2 | 2018 | 895 | 0.440 |
Why?
|
| Weight Loss | 4 | 2019 | 2673 | 0.440 |
Why?
|
| Hemodynamics | 3 | 2020 | 4164 | 0.410 |
Why?
|
| Disease Management | 3 | 2020 | 2498 | 0.400 |
Why?
|
| Heart Diseases | 3 | 2019 | 2800 | 0.400 |
Why?
|
| Registries | 5 | 2020 | 8434 | 0.380 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2015 | 347 | 0.370 |
Why?
|
| Hypoglycemia | 1 | 2018 | 883 | 0.370 |
Why?
|
| Risk Assessment | 10 | 2019 | 24049 | 0.360 |
Why?
|
| Biological Assay | 1 | 2013 | 630 | 0.360 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 899 | 0.340 |
Why?
|
| Critical Illness | 2 | 2019 | 2707 | 0.340 |
Why?
|
| Thiazoles | 1 | 2016 | 1501 | 0.320 |
Why?
|
| Aged | 29 | 2020 | 168617 | 0.310 |
Why?
|
| Troponin T | 1 | 2013 | 774 | 0.310 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1799 | 0.310 |
Why?
|
| Lipids | 1 | 2019 | 3336 | 0.310 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3087 | 0.310 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3207 | 0.300 |
Why?
|
| Middle Aged | 31 | 2020 | 219653 | 0.300 |
Why?
|
| North America | 3 | 2020 | 1282 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2018 | 12268 | 0.280 |
Why?
|
| Risk Factors | 17 | 2020 | 74167 | 0.280 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 3150 | 0.260 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 2161 | 0.250 |
Why?
|
| Treatment Outcome | 17 | 2020 | 64879 | 0.250 |
Why?
|
| Drug Therapy, Combination | 6 | 2019 | 6496 | 0.240 |
Why?
|
| Kidney | 2 | 2019 | 7066 | 0.240 |
Why?
|
| Male | 32 | 2020 | 358719 | 0.230 |
Why?
|
| Survival Rate | 7 | 2020 | 12800 | 0.230 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3368 | 0.230 |
Why?
|
| Hyphae | 1 | 2003 | 52 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 3193 | 0.220 |
Why?
|
| Female | 33 | 2020 | 390240 | 0.220 |
Why?
|
| Vacuoles | 1 | 2003 | 229 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 9194 | 0.200 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1581 | 0.200 |
Why?
|
| Humans | 46 | 2020 | 759255 | 0.200 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2020 | 60 | 0.180 |
Why?
|
| Creatinine | 2 | 2016 | 1907 | 0.180 |
Why?
|
| Candida albicans | 1 | 2003 | 377 | 0.180 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 2066 | 0.170 |
Why?
|
| Hospitalization | 1 | 2019 | 10734 | 0.170 |
Why?
|
| Recurrence | 3 | 2017 | 8469 | 0.170 |
Why?
|
| Time Factors | 7 | 2020 | 40109 | 0.160 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 124 | 0.160 |
Why?
|
| Chloroquine | 1 | 2020 | 277 | 0.160 |
Why?
|
| Critical Care | 3 | 2020 | 2697 | 0.160 |
Why?
|
| Appetite Regulation | 1 | 2019 | 84 | 0.160 |
Why?
|
| Hospital Mortality | 4 | 2020 | 5414 | 0.150 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2020 | 124 | 0.150 |
Why?
|
| Inflammation | 1 | 2018 | 10747 | 0.150 |
Why?
|
| Cardiology Service, Hospital | 1 | 2020 | 242 | 0.150 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 282 | 0.150 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2019 | 192 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2006 | 3443 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 281 | 0.150 |
Why?
|
| Alanine | 1 | 2020 | 606 | 0.150 |
Why?
|
| Canada | 2 | 2020 | 2124 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39216 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2020 | 535 | 0.140 |
Why?
|
| Plasma | 1 | 2020 | 583 | 0.140 |
Why?
|
| Adamantane | 1 | 2017 | 169 | 0.140 |
Why?
|
| Virus Internalization | 1 | 2020 | 495 | 0.130 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12522 | 0.130 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 361 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 428 | 0.130 |
Why?
|
| Pandemics | 3 | 2020 | 8609 | 0.130 |
Why?
|
| Dipeptides | 1 | 2017 | 410 | 0.130 |
Why?
|
| Receptors, Thrombin | 1 | 2015 | 132 | 0.120 |
Why?
|
| Calibration | 1 | 2017 | 816 | 0.120 |
Why?
|
| Patient Admission | 2 | 2019 | 1383 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2003 | 2939 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2017 | 597 | 0.120 |
Why?
|
| Receptor, PAR-1 | 1 | 2015 | 114 | 0.120 |
Why?
|
| Incidence | 5 | 2020 | 21336 | 0.120 |
Why?
|
| Azetidines | 1 | 2015 | 137 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2019 | 54204 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2016 | 3606 | 0.110 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 680 | 0.110 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 584 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 934 | 0.110 |
Why?
|
| Placebo Effect | 1 | 2017 | 511 | 0.110 |
Why?
|
| Thrombophilia | 1 | 2016 | 307 | 0.110 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 329 | 0.110 |
Why?
|
| Antimalarials | 1 | 2020 | 907 | 0.110 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 1155 | 0.110 |
Why?
|
| Cerebral Revascularization | 1 | 2015 | 244 | 0.110 |
Why?
|
| Remission Induction | 1 | 2018 | 2388 | 0.100 |
Why?
|
| Prediabetic State | 1 | 2018 | 546 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 281 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2016 | 6400 | 0.100 |
Why?
|
| Morbidity | 1 | 2018 | 1764 | 0.100 |
Why?
|
| Troponin I | 1 | 2016 | 634 | 0.100 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 941 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6532 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 932 | 0.100 |
Why?
|
| Neurology | 1 | 2019 | 775 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2015 | 841 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2020 | 2301 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 2168 | 0.090 |
Why?
|
| Internationality | 1 | 2015 | 1005 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2015 | 966 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2019 | 2979 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 2128 | 0.080 |
Why?
|
| Peripheral Arterial Disease | 1 | 2020 | 1310 | 0.080 |
Why?
|
| Cardiology | 1 | 2019 | 1720 | 0.080 |
Why?
|
| Atrial Fibrillation | 2 | 2017 | 5198 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2019 | 2092 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2003 | 12774 | 0.070 |
Why?
|
| Body Weight | 1 | 2018 | 4608 | 0.070 |
Why?
|
| Warfarin | 1 | 2016 | 1516 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3060 | 0.070 |
Why?
|
| Comorbidity | 3 | 2018 | 10547 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2018 | 1567 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1935 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 10827 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2013 | 1576 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2020 | 3214 | 0.070 |
Why?
|
| Life Style | 1 | 2017 | 3886 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2013 | 2123 | 0.060 |
Why?
|
| Echocardiography | 1 | 2018 | 4971 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2013 | 2777 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 13479 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 29561 | 0.060 |
Why?
|
| Risk | 1 | 2016 | 9623 | 0.060 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 1494 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 58867 | 0.060 |
Why?
|
| Forecasting | 1 | 2013 | 2931 | 0.060 |
Why?
|
| Sex Factors | 2 | 2017 | 10518 | 0.060 |
Why?
|
| RNA, Antisense | 1 | 2003 | 136 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 112 | 0.050 |
Why?
|
| United States | 4 | 2020 | 72237 | 0.050 |
Why?
|
| Age Factors | 1 | 2019 | 18394 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2015 | 10185 | 0.050 |
Why?
|
| Research Design | 1 | 2018 | 6168 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2003 | 283 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5317 | 0.050 |
Why?
|
| Serum | 1 | 2003 | 212 | 0.050 |
Why?
|
| G1 Phase | 1 | 2003 | 403 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2015 | 3460 | 0.050 |
Why?
|
| Nitrogen | 1 | 2003 | 351 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15815 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 13621 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2006 | 6131 | 0.050 |
Why?
|
| Culture Media | 1 | 2003 | 899 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 460 | 0.050 |
Why?
|
| Patient Selection | 1 | 2013 | 4269 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2016 | 4897 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2006 | 1512 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2017 | 12874 | 0.040 |
Why?
|
| Diet | 1 | 2017 | 8002 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2003 | 900 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5880 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2001 | 480 | 0.040 |
Why?
|
| Civil Defense | 1 | 2020 | 115 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2020 | 429 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2001 | 561 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 6649 | 0.040 |
Why?
|
| Cattle | 1 | 2003 | 3844 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 15264 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2006 | 2052 | 0.030 |
Why?
|
| Shock | 1 | 2018 | 318 | 0.030 |
Why?
|
| Cell Division | 1 | 2003 | 4463 | 0.030 |
Why?
|
| Kinetics | 1 | 2003 | 6380 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2019 | 487 | 0.030 |
Why?
|
| Aorta | 1 | 2003 | 2042 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 41247 | 0.030 |
Why?
|
| RNA Interference | 1 | 2003 | 2847 | 0.030 |
Why?
|
| Neoplasms | 1 | 2003 | 22019 | 0.030 |
Why?
|
| Catheterization | 1 | 2019 | 1433 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2001 | 2920 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1109 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 1501 | 0.030 |
Why?
|
| Adult | 2 | 2018 | 219390 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2003 | 3537 | 0.020 |
Why?
|
| Consensus | 1 | 2019 | 3095 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2018 | 1225 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3613 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2018 | 2253 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2018 | 1503 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5692 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2003 | 18968 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2475 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 2274 | 0.020 |
Why?
|
| Transfection | 2 | 2006 | 5783 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2001 | 8491 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2018 | 3731 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 616 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2019 | 8523 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2018 | 3836 | 0.010 |
Why?
|
| Animals | 3 | 2003 | 167838 | 0.010 |
Why?
|
| Melanocytes | 1 | 2006 | 511 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 58 | 0.010 |
Why?
|
| Point Mutation | 1 | 2006 | 1594 | 0.010 |
Why?
|
| Ataxia Telangiectasia | 1 | 2001 | 107 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 25860 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2006 | 1708 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2448 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 2015 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 5796 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 3604 | 0.010 |
Why?
|
| Heart Failure | 1 | 2019 | 11833 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 1972 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 80121 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 5214 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2001 | 8313 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 5796 | 0.000 |
Why?
|
| Apoptosis | 1 | 2001 | 9492 | 0.000 |
Why?
|
| Phenotype | 1 | 2001 | 16532 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2006 | 23362 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 21981 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 81138 | 0.000 |
Why?
|